Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Hypothesis: Treatment with Glatiramer acetate prevents deterioration of gait in multiple
sclerosis (MS) patients.
During the study patients will undergo a 3 dimensional gait analysis before starting
treatment with glatiramer acetate and after 1 year of treatment.